Abstracts tagged "giant cell arteritis"

Abstract Number: 200 • 2015 ACR/ARHP Annual Meeting
Mast Cell Regulation of Aortic IL-6 Expression Involves Histamine-1 Receptor, Suppressor of Cyotkine Signaling-1 and IL-10
Vineesh Raveendran¹, Jason Springer², Donald Smith³, Mehrdad Maz⁴ and Kottarappat Dileepan¹, ¹Department of Medicine, University of Kansas Medical Center, Kansas City, KS, ²Division of Allergy, Clinical Immunology and Rheumatology, University of Kansas Medical Center, Kansas City, KS, ³University of Kansas Medical Center, Kansas City, KS, ⁴Division of Rheumatology, University of Kansas Medical Center, Kansas City, KS
Background/Purpose: IL-6 plays an important role in the pathogenesis of large vessel vasculitis. Lipopolysaccharide (LPS), acting through toll-like receptor 4, enhances both the aortic expression…
Abstract Number: 1980 • 2015 ACR/ARHP Annual Meeting
Tocilizumab in Giant Cell Arteritis: A Multicentre Open-Label Study in France
Alexis Regent¹, Serge Redeker², Alban Deroux³, Pierre Kieffer⁴, Kim Heang Ly⁵, Maxime Dougados⁶, Claire Larroche⁷, Loïc Guillevin¹, Laurence Bouillet⁸, Olivier Espitia⁹, Nathalie Costedoat-Chalumeau¹⁰, Martin Soubrier¹¹, Benoit Brihaye¹², François Lifermann¹³, Guillaume Lefèvre¹⁴, Xavier Puéchal¹, Luc Mouthon¹, Eric Toussirot¹⁵ and GFEV and CRI, ¹Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, Paris, France, ²43 rue de l'isle, Ch Abbeville, Abbeville, France, ³Internal Medicine, CHU Grenoble, Grenoble, France, ⁴Hopital Emile Muller, Mulhouse Cedex 1, France, ⁵CHU de Limoges, Service de médecine interne, Limoges, France, ⁶Medicine Faculty, Paris-Descartes University, Paris, UPRES-EA 4058, Cochin Hospital, Rheumatology B, Paris, France, ⁷Internal Medicine, Paris, France, ⁸CHU, Grenoble, France, ⁹Internal Medicine, Nantes University Hospital, Nantes, France, ¹⁰Internal Medicine Department, Cochin Hospital, “René-Descartes Paris V” University, Paris, France, ¹¹Rheumatology department CHU Clermont-Ferrand, Clermont-Ferrand, France, ¹²Service de médecine interne et médecine polyvalente, Saint Quentin, France, ¹³CH Dax, Dax, France, ¹⁴Service de médecine interne, Centre National de Référence de la Sclérodermie Systémique, Hôpital Claude Huriez, CHRU Lille, Lille, France, ¹⁵Service de Rhumatologie, CHU J Minjoz, Besancon, France
Background/Purpose: To report the French experience on the efficacy and safety of tocilizumab (TCZ) in patients with giant cell arteritis (GCA) and outcome after treatment…
Abstract Number: 1233 • 2015 ACR/ARHP Annual Meeting
Epidemiology of GCA in Bergen (Western Norway) 1972-2012
Lene K Brekke¹, Andreas P Diamantopoulos², Elisabet L Esperø¹, Bjørg-Tilde Fevang^3,4, Johan G Brun^3,4 and Clara G Gjesdal^3,4, ¹Haugesund Hospital for Rheumatic Diseases, Haugesund, Norway, ²Rheumatology, Haugesund Hospital for Rheumatic Diseases, Haugesund, Norway, ³Department of Rheumatology, Haukeland University Hospital, Bergen, Norway, ⁴Department of Clinical Science, University of Bergen, Bergen, Norway
Background/Purpose: Giant cell arteritis (GCA) is the most common systemic vasculitis in persons older than 50 years. The highest incidence rates of the disease have…
Abstract Number: 2156 • 2015 ACR/ARHP Annual Meeting
Damage Assessment in Giant Cell Arteritis
Tanaz A. Kermani¹, Antoine G. Sreih², David Cuthbertson³, Simon Carette⁴, Gary S. Hoffman⁵, Nader A. Khalidi⁶, Curry L. Koening⁷, Carol A. Langford⁵, Carol A. McAlear⁸, Paul A. Monach⁹, Larry W. Moreland¹⁰, Christian Pagnoux⁴, Philip Seo¹¹, Kenneth J. Warrington¹², Steven R. Ytterberg¹² and Peter A. Merkel¹³, ¹Rheumatology, University of California Los Angeles, Santa Monica, CA, ²Department of Rheumatology, University of Pennsylvania, Philadelphia, PA, ³Biostatistics and Informatics, Department of Pediatrics, University of South Florida, Tampa, FL, ⁴Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁵Rheumatology, Cleveland Clinic, Cleveland, OH, ⁶McMaster University, Hamilton, ON, Canada, ⁷Rheumatology, University of Utah, Salt Lake City, UT, ⁸Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ⁹Rheumatology, Boston University School of Medicine, Boston, MA, ¹⁰Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ¹¹Division of Rheumatology, Johns Hopkins University, Baltimore, MD, ¹²Rheumatology, Mayo Clinic, Rochester, MN, ¹³Penn Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: This study aimed to 1) catalogue damage in a longitudinal cohort of patients with giant cell arteritis (GCA) and 2) evaluate predictors of…
Abstract Number: 1340 • 2015 ACR/ARHP Annual Meeting
Value of 18F-FDG PET for Therapeutic Assessment in Patients with Polymyalgia Rheumatica Treated in First Line By Tocilizumab
Xavier Palard¹, Solene Querellou², Maelenn Gouillou³, Alain Saraux^4,5, Thierry Marhadour⁶, Florent Garrigues⁷, Ronan Abgral⁸, Pierre-Yves Salaun⁸ and Valerie Devauchelle^9,10, ¹Department of nuclear medicine, University hospital of Brest, Brest, France, ²Department of nuclear medicine, Université Européenne de Bretagne; Université de Brest; EA3878 (GETBO) IFR148, Brest, French Polynesia, ³Clinical Investigation Centre (CIC) 1412, CHU Cavale Blanche- Institut National de la Santé et de la Recherche Médicale (INSERM), Brest, France, ⁴Department of rheumatology and unit of immunology (EA 2216), Université Brest Occidentale, Brest, France, ⁵Rheumatology Department, CHU de la Cavale Blanche, Brest Cedex, France, ⁶CHU La Cavale Blanche, Brest, France, ⁷Radiology department, Cavale Blanche Hospital and Brest Occidentale University, Brest, France, ⁸Department of nuclear medicine, Université Européenne de Bretagne; Université de Brest; EA3878 (GETBO) IFR148, Brest, France, ⁹Service de Rhumatologie, CHU Brest, Brest, France, ¹⁰Rheumatology, Brest university medical school, EA 2216, UBO and CHU de la Cavale Blanche,, Brest, France
Background/Purpose: To evaluate the interest of 18F-FDG positron emission tomography-computed tomography (PET-CT) for therapeutic assessment in polymyalgia rheumatica (PMR) patients undergoing tocilizumab (TCZ) therapy at first…
Abstract Number: 2157 • 2015 ACR/ARHP Annual Meeting
Relapse Characteristics and Glucocorticoid Use in Patients with Biopsy-Proven Giant Cell Arteritis
Matthew J. Koster¹, Cristian Labarca², Cynthia S. Crowson³, Ashima Makol¹, Steven R. Ytterberg⁴, Eric L. Matteson¹ and Kenneth J. Warrington¹, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Rheumatology, Clinica Alemana Universidad del Desarrollo, Santiago, Chile, ³Health Sciences Research, Mayo Clinic, Rochester, MN, ⁴Rheumatology Division, Mayo Clinic, Rochester, MN
Background/Purpose: Relapses in patients with giant cell arteritis (GCA) are common and often lead to higher cumulative use of glucocorticoids. This study aims to evaluate…
Abstract Number: 1953 • 2015 ACR/ARHP Annual Meeting
Identification of Genetic Factors Associated with Clinical Manifestations of Giant Cell Arteritis through a Stratified Large-Scale Analysis
Ana Márquez¹, Francisco David Carmona², Maria C. Cid³, José Hernández-Rodríguez³, Roser Solans⁴, Marc Ramentol⁴, Santos Castañeda⁵, Jose A. Miranda-Filloy⁶, Inmaculada C. Morado⁷, Javier Narváez⁸, Eugenio De Miguel⁹, Bernardo Sopeña¹⁰, Jordi Monfort¹¹, Maria Jesus Garcia-Villanueva¹², Norberto Ortego-Centeno¹³, Miguel Angel Gonzalez-Gay¹⁴, Javier Martín¹⁵ and Spanish GCA Group, ¹Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, PTS-Granada and Systemic Autoimmune Diseases Unit, Hospital Clínico San Cecilio, Granada, Spain, ²Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, PTS-Granada, Granada, Spain, ³Vasculitis Research Unit, Department of Autoimmune Diseases, Hospital Clínic University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, ⁴Autoimmune Systemic Diseases Unit, Department of Internal Medicine, Hospital Vall d’Hebron, Autonomous University of Barcelona, Barcelona, Spain, ⁵Department of Rheumatology, Hospital de la Princesa, IIS-Princesa, Madrid, Spain, ⁶Department of Rheumatology, Hospital Xeral-Calde, Lugo, Spain, ⁷Department of Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, ⁸Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ⁹Department of Rheumatology, Hospital Universitario La Paz, Madrid, Spain, ¹⁰Department of Internal Medicine, Complejo Hospitalario Universitario de Vigo, Vigo, Spain, ¹¹Department of Rheumatology, Grup de recerca cel•lular en inflamació i cartílag. IMIM (Institut de Recerca Hospital del Mar), Barcelona, Spain, ¹²Department of Rheumatology, Hospital Ramón y Cajal, Madrid, Spain, ¹³Systemic Autoimmune Diseases Unit, Hospital Clínico San Cecilio, Granada, Spain, ¹⁴Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ¹⁵Instituto de Parasitología y Biomedicina López- Neyra, IPBLN-CSIC, PTS-Granada, Granada, Spain
Background/Purpose: Giant cell arteritis (GCA) is a large-vessel vasculitis that primarily affects the aorta and external carotid arteries and their branches, leading to ischemic manifestations…
Abstract Number: 2159 • 2015 ACR/ARHP Annual Meeting
Second Temporal Artery Biopsies in Patients with Temporal Arteritis (TA)
John Fritzlen¹, Brian Younge², Cornelia M. Weyand³, Gene G. Hunder⁴, Jorg Goronzy⁵, Kenneth J. Warrington⁴ and Joseph Maleszewski¹, ¹Anatomical Pathology, Mayo Clinic, Rochester, MN, ²Ophthalmology, Mayo Clinic, Rochester, MN, ³Stanford, Stanford, CA, ⁴Rheumatology, Mayo Clinic, Rochester, MN, ⁵Emory University School of Medicine, Lowance Center for Human Immunology and Rheumatology, Atlanta, GA
Background/Purpose: While many manifestations of TA improve quickly after starting glucocorticoid therapy, vascular inflammation appears to persist. To obtain more information about the duration of…
Abstract Number: 790 • 2014 ACR/ARHP Annual Meeting
Correlations Between Histopathological Findings and Clinical Manifestations in a Large Monocentric Cohort of Patients with Biopsy-Proven Giant Cell Arteritis
Luigi Boiardi¹, Francesco Muratore¹, Giovanna Restuccia², Alberto Cavazza³, Pierluigi Macchioni¹, Giuseppe Germanò¹, Nicolò Pipitone¹ and Carlo Salvarani¹, ¹Rheumatology Unit, Arcispedale S Maria Nuova, Reggio Emilia, Italy, ²Rheumatology Unit, Arcispedale S Maria Nuova, Reggio Emilia, Italy, ³Pathology Unit, Arcispedale S Maria Nuova, Reggio Emilia, Italy
Background/Purpose: Giant cell arteritis (GCA) is a vasculitis that involves large and medium sized arteries in patients older than 50 years. Temporal artery biopsy (TAB)…
Abstract Number: 787 • 2014 ACR/ARHP Annual Meeting
Cardiovascular Risk Factors and Incident Giant Cell Arteritis
Gunnar Tomasson¹, Jóhannes Björnsson², Vilmundur Gudnason³, Yuqing Zhang⁴ and Peter A. Merkel⁵, ¹Dept of Public Health Sciences, University of Iceland, Reykiavik, Iceland, ²Department of Pathology, Akureyri Hospital, Akureyri, Iceland, ³The Icelandic Heart Association, Kopavogur, Iceland, ⁴Boston University School of Medicine, Boston, MA, ⁵University of Pennsylvania, Philadelphia, PA
Background/Purpose: To assess the effect of cardiovascular risk factors on incidence GCA within a longitudinal cohort study in which detailed information on cardiovascular risk factors…
Abstract Number: 784 • 2014 ACR/ARHP Annual Meeting
Novel Inhibitory Effects of Mast Cells in Aortitis Involves Aortic Expression of Suppressor of Cytokine Signaling-1
Jason Springer¹, Vineesh Raveendran², Donald Smith³, Mehrdad Maz⁴ and Kottarappat Dileepan², ¹Department of Rheumatology, University of Kansas Medical Center, Kansas City, KS, ²Department of Medicine, University of Kansas Medical Center, Kansas City, KS, ³University of Kansas Medical Center, Kansas City, KS, ⁴Division of Rheumatology, University of Kansas Medical Center, Kansas City, KS
Background/Purpose Early in the pathogenesis of Giant Cell Arteritis (GCA) dendritic cells interact with T cells of both Th1 and Th17 origin. IL-6; released by…
Abstract Number: 782 • 2014 ACR/ARHP Annual Meeting
Temporal Artery Microbiome in Giant Cell Arteritis
Alison Clifford*¹, Pauline Funchain*^2,3,4, Lisa Lystad⁵, Charissa Peterson⁴, Jessica Altemus⁴, Gary S. Hoffman¹ and Charis Eng^2,3,4,6, ¹Center for Vasculitis Care and Research, Cleveland Clinic Foundation, Cleveland, OH, ²Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH, ³Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH, ⁴Genomic Medicine Institute, Lerner Research Institute, Cleveland, OH, ⁵Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, OH, ⁶Department of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, Cleveland, OH
Background/Purpose: Whether infectious agents play a part in giant cell arteritis (GCA) remains controversial. We have performed the first microbiome study of snap-frozen temporal arteries,…
Abstract Number: 2786 • 2014 ACR/ARHP Annual Meeting
Aortitis: Outcomes from a Cohort of 196 Patients
Alison Clifford¹, Amr Arafat², Jahanzaib Idrees², Eric Roselli², Carmela D. Tan³, E. Rene Rodriguez³, Lars Svensson², Eugene Blackstone² and Gary S. Hoffman¹, ¹Center for Vasculitis Care and Research, Cleveland Clinic Foundation, Cleveland, OH, ²Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic Foundation, Cleveland, OH, ³Department of Anatomic Pathology, Cleveland Clinic Foundation, Cleveland, OH
Background/Purpose: Idiopathic aortitis is a rare diagnosis that may occur in the context of a primary systemic vasculitis, as part of a systemic autoimmune disease,…
Abstract Number: 780 • 2014 ACR/ARHP Annual Meeting
Novel Roles for Zyxin in the Pathogenesis of Giant Cell Arteritis
Rie Karasawa¹, Paul A. Monach², Mayumi Tamaki¹, Takahiro Okazaki³, Masamichi Oh-Ishi⁴, Yoshio Kodera⁴, Toshiko Sato¹, Shoichi Ozaki⁵, Kaiyu Jiang⁶, Kazuo Yudoh¹, James N. Jarvis⁷ and Peter A. Merkel⁸, ¹Institute of Medical Science, St. Marianna University School of Medicine, Kawasaki, Japan, ²Section of Rheumatology, Vasculitis Center, Boston University School of Medicine, Boston, MA, ³Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ⁴School of Science, Kitasato University, Sagamihara, Japan, ⁵Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ⁶415 Carmen Road, Apt. 1, The University at Buffalo, Buffalo, NY, ⁷Pediatrics, The University at Buffalo, Buffalo, NY, ⁸Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose �:The mechanisms of the blood vessel injury in giant cell arteritis (GCA), a systemic vasculitis characterized by inflammation of large- and medium-sized vessels, remain…
Abstract Number: 2770 • 2014 ACR/ARHP Annual Meeting
Polymyalgia Rheumatica Relapse and “Silence” Large Vessel Vasculitis. Is There Any Association?
Stavros Chrysidis¹, Philip Rask Lage-Hansen¹ and Andreas P. Diamantopoulos², ¹Department of Rheumatology, Hospital of Southwest Denmark, Esbjerg, Denmark, ²Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway
Background/Purpose Large Vessel Vasculitis (LVV) can present with heterogeneous clinical manifestations, which range from general symptoms (fever, loss of weight) to the classic symptoms of …

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].